Monophosphoryl Lipid A (Synthetic)

By generating a pathogen-specific immune response before infection, vaccination is recognized as an effective way to prevent infection. Typically, immunization with vaccine antigens alone does not induce a robust or durable immune response - leading to a failure of protective immunity against infection. Therefore, adjuvants are needed to enhance the cellular or humoral immune response after immunization. Monophosphoryl lipid A (MPLA) is either extracted from bacterial lipid A or by chemical synthesis.MPLA has been used:• as a component of cobalt porphyrin-phospholipid (Co-PoP) liposomes for the immunization of mice with membrane proximal external region (MPER) of the gp41 envelope protein • as an adjuvant along with dimethyldioctadecylammonium bromide(DDA) for C. muridarum recombinant membrane protein based multi-subunit vaccine• as toll-like receptor-4 (TLR4) agonist adjuvant for respiratory syncytial virus (RSV) fusion (F) protein FI-RSV vaccine. Specification: 0.99 Molecular Formula: C96H184N3O22P Molecular Weight: 1763.47 PubChem CID: 134687617 Isomeric SMILES: CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1OC[C@@H]2[C@H]([C@@H]([C@H]([C@H](O2)O)NC(=O)C[C@@H](CCCCCCCCCCC)O)OC(=O)C[C@@H](CCCCCCCCCCC)O)O)CO)OP(=O)(O)[O-])OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC.[NH4+] Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/M130160-SCI_7ed8b17a6ea05216c214229370ad84f6.pdf